MRK catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
December 2026
- Primary completion Dec 14, 2026Sponsor estimatePhase 1NCT07776665A Clinical Trial of Enlicitide (MK-0616) Formulations in Healthy Participants (MK-0616-044)Merck Sharp & Dohme LLC · HealthyActive, not recruitingMRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 15, 2026Sponsor estimatePhase 1NCT07748351A Clinical Trial of Multiple Formulations of MK-4082 in Healthy Overweight and Obese Participants (MK-4082-007)Merck Sharp & Dohme LLC · HealthyActive, not recruitingMRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 22, 2026Sponsor estimatePhase 1/Phase 2NCT05468697A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell...Merck Sharp & Dohme LLC · Renal Cell CarcinomaActive, not recruitingMRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 1NCT04184050Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Multiple Myeloma in RelapseActive, not recruitingMRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 1NCT07300085A Trial to Evaluate the Effect of CD388/MK1406 on the Immunogenicity of Fluzone® HD Vaccine (CD388.SQ.1.08/MK-1406-007)Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Healthy ParticipantsRecruitingMRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
January 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Jan 19, 2027Sponsor estimate | NCT07600775A Clinical Trial of MK-8527 and Rifampin in Adult Participants With Latent Tuberculosis Infection (MK-8527-019)Merck Sharp & Dohme LLC · Human Immunodeficiency Virus (HIV) | MRKLead | Phase 1 | Not yet recruiting | Locked | Locked | Locked |
| Jan 29, 2027Sponsor estimate | NCT06688058A Trial to Evaluate Tolerability and Immunogenicity of V540D in Healthy Adults (V540D-004)Merck Sharp & Dohme LLC · Healthy | MRKLead | Phase 1 | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Jan 19, 2027Sponsor estimatePhase 1NCT07600775A Clinical Trial of MK-8527 and Rifampin in Adult Participants With Latent Tuberculosis Infection (MK-8527-019)Merck Sharp & Dohme LLC · Human Immunodeficiency Virus (HIV)Not yet recruitingMRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 29, 2027Sponsor estimatePhase 1NCT06688058A Trial to Evaluate Tolerability and Immunogenicity of V540D in Healthy Adults (V540D-004)Merck Sharp & Dohme LLC · HealthyActive, not recruitingMRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
February 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Feb 1, 2027Sponsor estimate | NCT07734610A Clinical Trial of Nemtabrutinib in Participants With Severe Kidney Disease (MK-1026-027)Merck Sharp & Dohme LLC · Severe Renal Impairment | MRKLead | Phase 1 | Recruiting | Locked | Locked | Locked |
| Feb 5, 2027Sponsor estimate | NCT07743151A Clinical Trial of MK-1406 in Healthy Participants (MK-1406-008)Merck Sharp & Dohme LLC · Healthy | MRKLead | Phase 1 | Recruiting | Locked | Locked | Locked |
| Feb 9, 2027Sponsor estimate | NCT07862621A Clinical Trial of MK-6916 With Midazolam and Rosuvastatin in Healthy Participants (MK-6916-012)Merck Sharp & Dohme LLC · Healthy | MRKLead | Phase 1 | Not yet recruiting | Locked | Locked | Locked |
- Primary completion Feb 1, 2027Sponsor estimatePhase 1NCT07734610A Clinical Trial of Nemtabrutinib in Participants With Severe Kidney Disease (MK-1026-027)Merck Sharp & Dohme LLC · Severe Renal ImpairmentRecruitingMRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 5, 2027Sponsor estimatePhase 1NCT07743151A Clinical Trial of MK-1406 in Healthy Participants (MK-1406-008)Merck Sharp & Dohme LLC · HealthyRecruitingMRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 9, 2027Sponsor estimatePhase 1NCT07862621A Clinical Trial of MK-6916 With Midazolam and Rosuvastatin in Healthy Participants (MK-6916-012)Merck Sharp & Dohme LLC · HealthyNot yet recruitingMRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 10 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.